| Ticker: | ZURA |
| Current Price: | $4.17 |
| % Daily Change: | 5.30% |
| Volume (1,000s): | 2,084.56 |
| Average Volume (1,000s): | 0.00 |
| Market Cap (M): | $396.14 |
| 1/2/2024 Price: | $2.58 |
| Change Since Inception: | 61.63% |
1489 W. Warm Springs Road, Suite 110
Henderson, NV 89014
United States
Zura Bio Limited (NASDAQ: ZURA) is a clinical-stage biotechnology company developing dual-pathway antibodies for autoimmune and inflammatory diseases. Its lead candidate, tibulizumab, is a bispecific antibody that blocks both IL-17 and BAFF, two drivers of inflammation and fibrosis, and the company says it is the first and only antibody of its kind. Tibulizumab is in two fully enrolled Phase 2 trials: TibuSHIELD in hidradenitis suppurativa, with topline data expected in the fourth quarter of 2026, and TibuSURE in systemic sclerosis, with data expected in the first half of 2027. Zura plans to start a third Phase 2 study, in polymyalgia rheumatica, by year end. Two additional antibodies, torudokimab and crebankitug, have completed Phase 1 studies. Founded in 2022, Zura is headquartered in Henderson, Nevada.